Page last updated: 2024-10-15

2'(3')-o-(n-methyl)anthraniloylguanosine 5'-triphosphate

Description

2'(3')-O-(N-methyl)anthraniloylguanosine 5'-triphosphate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'-MANT-GTP : A purine ribonucleoside 5'-triphosphate that is GTP substituted at the 3' position by an N-methylanthraniloyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135509141
CHEMBL ID403351
CHEBI ID145576
MeSH IDM0176424

Synonyms (17)

Synonym
ONM ,
3'-o-(n-methylanthraniloyl)-guanosine-5'-triphosphate
1U0H
1TL7
mantgtp
CHEMBL403351
2'(3')-o-(n-methyl)anthraniloylguanosine 5'-triphosphate
CHEBI:145576
3'-mant-gtp
3'-o-[2-(methylamino)benzoyl]guanosine 5'-(tetrahydrogen triphosphate)
3'-o-(n-methylanthraniloyl)guanosine triphosphate
85287-57-6
guanosine 5'-(tetrahydrogen triphosphate), 3'-(2-methylamino)benzoate
DTXSID30234492
3'-o-(n-methylanthraniloyl)guanosine-5'-o-triphosphate
3'-o-{[2-(methylamino)phenyl]carbonyl}guanosine 5'-(tetrahydrogen triphosphate)
Q27464154
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorescent probeA role played by a fluorescent molecular entity used to study the microscopic environment by fluorescence spectroscopy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
purine ribonucleoside 5'-triphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Adenylate cyclase, type VCanis lupus familiaris (dog)Ki0.06100.01200.06100.1100AID977610
Chain B, Adenylate cyclase, type IIRattus norvegicus (Norway rat)Ki0.06100.01200.06100.1100AID977610
Chain A, Adenylate cyclase, type VCanis lupus familiaris (dog)Ki0.06100.01200.06100.1100AID977610
Chain B, Adenylate cyclase, type IIRattus norvegicus (Norway rat)Ki0.06100.01200.06100.1100AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005The Journal of biological chemistry, Feb-25, Volume: 280, Issue:8
Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3')-O-(N-Methylanthraniloyl)-guanosine 5 '-triphosphate.
AID310935Inhibition of adenylyl cyclase2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (26.32)18.2507
2000's11 (57.89)29.6817
2010's3 (15.79)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]